Lumiradx covid-19 & flu a/b rapid antigen test achieves ce marking

London, dec. 23, 2021 /prnewswire/ -- lumiradx (nasdaq: lmdx), a next-generation point of care diagnostics company, today announced its sars-cov-2 & flu a/b antigen test has achieved ce marking. the microfluidic immunofluorescence assay can quickly verify potential infection for patients suspected of influenza and/or covid-19, helping to identify and differentiate the underlying cause of respiratory illness and to inform treatment decisions at the point of care.
LMDX Ratings Summary
LMDX Quant Ranking